Episode
Adapting to Industry Rebound: The Next Phase of Clinical Trials
- Podcast
- Moving Medicine Forward
- Published
- Jun 3, 2026
- Duration seconds
- 1703
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/moving-medicine-forward-6832193/episodes/adapting-to-industry-rebound-the-next-phase-of-clinical-trials/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/moving-medicine-forward-6832193/adapting-to-industry-rebound-the-next-phase-of-clinical-trials.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What does a recovering clinical research market actually look like in 2026? In this episode, Joel White , Owner of Market Cap Consulting, and Ryan Gifford , Vice President, Global Laboratory Services, Business Development & Client Management at CTI, join us to unpack the state of the industry—from the rebound in biotech funding to the growing importance of execution, site relationships, and smarter trial design. We explore how increasing complexity is shaping partnerships, how labs and decentralized models are evolving, and what it will take to keep trials on track. Looking ahead, the conversation offers a practical perspective on what the next 12–18 months could bring. 01:00 Guest backgrounds: Joel White (Market Cap Consulting) and Ryan Gifford (CTI) 02:45 Market recovery and funding trends 05:15 Trial success: early collaboration and site relationships 08:15 Funding challenges and execution impacts 10:30 Reducing site burden through lab operations and logistics 14:15 Decentralized trials and patient experience 16:25 Regulatory shifts, AI, and growing data complexity 19:30 Future outlook: partnerships and global trial expansion 23:30 Key takeaways and rapid-fire insights